Every Form 4 that First Tracks Biotherapeutics, Inc. (TRAXV) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TRAXV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TRAXV filings page.
First Tracks Biotherapeutics director Ware J. Anthony received new equity awards. He was granted stock options for 42,000 shares of common stock at an exercise price of $17.81 per share and 15,000 restricted stock units, both as compensation awards rather than open‑market purchases.
The 42,000 stock options vest in equal monthly installments over 12 months starting on June 12, 2026, and expire on May 11, 2036, if not exercised. The 15,000 RSUs vest 100% on the date of the company’s 2027 annual meeting of shareholders, subject to continued service, and each RSU will settle into one share for no cash consideration.
In addition to these grants, he also holds options to purchase up to 131,585 additional shares of common stock under prior awards, which continue to vest according to their own terms.
First Tracks Biotherapeutics director John P. Schmid received new equity awards as part of his compensation. He was granted stock options covering 42,000 shares of common stock at an exercise price of $17.81 per share, expiring on 2036-05-11.
The option vests in equal monthly installments, with 1/12 of the shares vesting each month starting on 2026-06-12, as long as he continues serving the company. Schmid also received 15,000 restricted stock units, each representing a right to one share of common stock at no cost upon settlement.
These RSUs vest 100% on the date of First Tracks Biotherapeutics’ 2027 annual shareholder meeting, subject to continued service. In addition to the newly granted 42,000 options, he already holds options to purchase up to an aggregate of 107,320 shares of common stock that vest according to their existing terms.
First Tracks Biotherapeutics director Magda Marquet received new equity awards as part of her compensation. She was granted options to buy 42,000 shares of common stock at an exercise price of $17.81 per share, expiring on May 11, 2036. These options vest monthly, with 1/12 of the total vesting each month starting on June 12, 2026, as long as she continues serving the company.
She also received 15,000 restricted stock units, each representing the right to receive one share of common stock for no cash payment. All of these RSUs vest on the date of First Tracks’ 2027 annual meeting of shareholders, subject to her continued service. In addition to this new option grant, she already holds options to purchase up to 70,104 shares of common stock that vest according to their existing terms.
First Tracks Biotherapeutics director Rita Jain received new equity awards in the form of options and restricted stock units. She was granted options to buy 42,000 shares of common stock at an exercise price of $17.81 per share, expiring on May 11, 2036.
She also received 15,000 restricted stock units, each representing one share of common stock upon settlement for no cash consideration. The RSUs vest 100% on the date of the company’s 2027 annual shareholder meeting, while the options vest in 12 equal monthly installments starting June 12, 2026 as long as she continues serving the company.
First Tracks Biotherapeutics director John A. Orwin received new equity awards. He was granted options to buy 42,000 shares of common stock at an exercise price of $17.81 per share, vesting in 12 equal monthly installments starting on June 12, 2026, as long as he continues serving the company.
Orwin also received 15,000 restricted stock units, each representing one share of common stock for no cash cost upon settlement. These RSUs vest 100% on the date of the company’s 2027 annual shareholder meeting, subject to continued service. A footnote notes he also holds other options covering up to 55,181 shares that vest under their existing terms.
First Tracks Biotherapeutics director Dennis M. Fenton received new equity awards as part of his compensation. He was granted options to buy 42,000 shares of common stock at an exercise price of $17.81 per share, expiring on May 11, 2036. These options vest in equal monthly installments over 12 months beginning June 12, 2026, so he earns them gradually by continuing to serve the company.
He was also granted 15,000 restricted stock units, each representing one share of common stock for no cash payment. These RSUs vest in full on the date of the company’s 2027 annual shareholder meeting, if he is still providing service. In addition to the 42,000 new options, he holds other options to purchase up to 97,827 shares that vest under their existing terms.
First Tracks Biotherapeutics granted Chief Business Officer Benjamin Stone new equity awards tied to the company’s common stock. He received an option to buy 72,300 shares at an exercise price of $17.81 per share, expiring on May 11, 2036. The option vests 25% on May 12, 2027, then in equal monthly installments over four years, conditioned on continued service.
Stone was also awarded 26,700 restricted stock units, each representing one share of common stock upon settlement for no consideration. These RSUs vest 25% annually starting on May 12, 2027, also subject to ongoing service. In addition to the new grant, he already holds options to purchase up to 337,140 shares of common stock under existing award terms.
First Tracks Biotherapeutics, Inc. reported that President and CEO Daniel Faga received new equity awards as part of his compensation. He was granted options to purchase 271,100 shares of common stock at an exercise price of $17.81 per share, expiring on May 11, 2036.
These stock options vest 25% on May 12, 2027, then in equal monthly installments over 48 months, contingent on continued service. Faga also received 100,200 restricted stock units, each representing one share of common stock for no cash consideration, vesting 25% annually from May 12, 2027 until fully vested, also subject to continued service. A footnote states he holds additional options to purchase up to 1,035,941 shares that vest under their own terms.
First Tracks Biotherapeutics Chief Financial Officer Ajim Tamboli received new equity awards as part of compensation. On May 12, 2026, he was granted options to purchase 13,600 shares of common stock at an exercise price of $17.81 per share, expiring on May 11, 2036.
The option vests 25% on May 12, 2027 and then in equal monthly installments over the following three years, contingent on continued service. He also received 5,000 restricted stock units, with 25% of the RSUs vesting annually starting on May 12, 2027, also subject to continued service.
In addition to this new grant of 13,600 options, he holds other options covering up to 123,700 shares of common stock that vest according to their existing terms. These awards are non-cash grants and do not represent open-market share purchases or sales.
First Tracks Biotherapeutics Chief Medical Officer Paul F. Lizzul received new equity awards. He was granted employee stock options for 72,300 shares of common stock at an exercise price of $17.81 per share, expiring on May 11, 2036. These options vest 25% on May 12, 2027, then 1/48 of the total shares monthly until fully vested, contingent on continued service.
He also received 26,700 restricted stock units, each representing a right to receive one share of common stock for no cash payment. The RSUs vest 25% annually starting on May 12, 2027, subject to ongoing service. There were no open-market purchases or sales reported. A footnote states he also holds separate options to purchase up to 507,310 shares of common stock that vest under their own terms.
First Tracks Biotherapeutics Chief Financial Officer Ajim Tamboli reported equity compensation awards in the form of stock options and restricted stock units. He received employee stock options to buy 41,234, 41,233 and 41,233 shares of common stock at exercise prices of $19.00, $18.87 and $17.00 per share, each expiring in 2036. He also received 45,700 restricted stock units, each representing the right to receive one share for no cash payment. The options vest 25% on April 20, 2027 and then monthly, while the RSUs vest 25% on the same date and then in equal annual installments, in each case contingent on continued service.
First Tracks Biotherapeutics, Inc. insider filing shows funds advised by EcoR1 Capital, LLC sold 4,705,575 shares of Common Stock at $13.8134 per share in a transaction coded as an open-market or private sale.
According to the disclosure, the shares are held directly by EcoR1-managed funds for the benefit of their investors, with EcoR1 and its control person Oleg Nodelman only indirectly deemed beneficial owners to the extent of their pecuniary interests. A footnote states the funds sold these shares in a private placement described in a separate Form 8-K.
The filing notes that EcoR1 Capital Fund Qualified L.P. sold 4,420,064 of the shares in this transaction and, after the sale, holds 2,981,908 First Tracks Biotherapeutics common shares. Overall indirect holdings reported for EcoR1 after the transaction total 3,174,519 shares, indicating the funds retain a sizable, but reduced, position.
Lizzul Paul F. reported acquisition or exercise transactions in this Form 4 filing.
First Tracks Biotherapeutics, Inc. Chief Medical Officer Paul F. Lizzul reported equity awards and holdings tied to the spin-off from AnaptysBio, Inc. On the common stock line, he is shown holding 42,669 shares directly.
Footnotes explain that these shares, as well as stock options and restricted stock units, were received or adjusted in connection with a pro rata distribution under a Separation and Distribution Agreement between AnaptysBio and First Tracks. Multiple RSU awards and stock options over First Tracks common stock were listed, with future vesting over several years, reflecting compensation and spin-off adjustments rather than open-market trading.
First Tracks Biotherapeutics director Ware J. Anthony reported equity awards and holdings following the company’s spin-off from AnaptysBio. He holds 9,630 shares of common stock received in the pro rata distribution tied to the Separation and Distribution Agreement dated April 20, 2026.
He also acquired multiple stock options and restricted stock units that were adjusted from prior AnaptysBio awards. These include RSUs for 4,000 and 6,030 shares of common stock, each RSU representing one share upon settlement at no cost, plus several fully vested and time‑vested stock options with exercise prices between $3.97 and $28.03 per share and expirations between 2027 and 2036. The RSUs are scheduled to vest in full at the company’s 2026 and 2027 annual shareholder meetings, subject to continued service.
Schmid John P. reported acquisition or exercise transactions in this Form 4 filing.
First Tracks Biotherapeutics director John P. Schmid reported equity awards and spin-off related holdings. He directly holds 31,622 shares of common stock received in connection with the spin-off from AnaptysBio. Schmid also holds restricted stock units and multiple stock option grants that provide additional exposure to First Tracks shares.
He was granted 4,000 RSUs vesting in full on the company’s 2026 annual shareholder meeting and 6,030 RSUs vesting in full at the 2027 meeting, each settling into one share of common stock per unit for no cash cost. Footnotes state that his stock options and RSUs were adjusted under a Separation and Distribution Agreement so that awards now cover both First Tracks and AnaptysBio. One option grant is fully vested, while another vests in 12 equal monthly installments beginning February 6, 2026.
Orwin John A reported acquisition or exercise transactions in this Form 4 filing.
First Tracks Biotherapeutics director John A. Orwin reported new equity awards tied to the spin-off from AnaptysBio. He holds 10,665 shares of common stock received in a pro rata distribution at separation.
On April 20, 2026, he was credited with three restricted stock unit blocks of 6,000, 6,030 and 1,300 RSUs, each representing one common share upon settlement for no cash consideration. These RSUs include tranches vesting in thirds on September 15, 2024, 2025 and 2026, plus separate grants vesting 100% on the company’s 2026 and 2027 annual shareholder meeting dates, subject to continued service.
He also received or had adjusted stock options over common shares, including 8,250 options at $11.75 per share that are fully vested, and additional options for 16,510 shares at $3.97, 16,510 at $5.67, and 10,600 and 3,311 at $5.22 per share, with expirations between 2033 and 2036 and vesting schedules commencing monthly from February 6, 2026. Footnotes state these option and RSU positions were adjusted so that AnaptysBio awards became awards in both AnaptysBio and First Tracks under their Separation and Distribution Agreement.
First Tracks Biotherapeutics director Dennis M. Fenton reported new equity awards tied to the spin-off from AnaptysBio and his board service. He now directly holds 4,965 shares of common stock received in the pro rata distribution from AnaptysBio.
On April 20, 2026, he acquired 4,000 and 6,030 Restricted Stock Units, each RSU representing one share of common stock upon settlement for no consideration. He also received multiple stock options to buy First Tracks common stock at exercise prices ranging from $3.97 to $31.82 per share with expirations between 2028 and 2036. Some options are fully vested, while others vest monthly starting February 6, 2026, and certain RSUs vest 100% on the company’s 2026 and 2027 annual meeting dates.
First Tracks Biotherapeutics, Inc. director Rita Jain reported equity awards and holdings in connection with the company’s separation from AnaptysBio. She directly holds 11,864 shares of common stock, including shares received in the spin-off distribution from AnaptysBio.
On April 20, 2026, Jain was credited with multiple stock options and restricted stock units (RSUs) that reflect adjustments under the Separation and Distribution Agreement. The filing lists stock options covering 5,500, 16,510, 16,510, 8,015, and 10,600 shares of common stock at exercise prices ranging from $3.97 to $11.75 per share, with expirations between 2033 and 2036. One option is fully vested, while another vests in twelfths monthly starting on February 6, 2026.
The RSU awards cover 4,000, 6,030, and 1,300 units, each representing the right to receive one share of common stock for no consideration. RSUs vest in tranches on June 15, 2024, June 15, 2025, and June 15, 2026, and in full on the dates of the issuer’s 2026 and 2027 annual meetings of shareholders, in each case subject to continued service.
First Tracks Biotherapeutics, Inc. reported an insider transaction by AnaptysBio, Inc., a ten percent owner, related to a corporate restructuring. AnaptysBio previously held 100 shares of First Tracks common stock, which represented all issued and outstanding shares.
On the April 20, 2026 record date, AnaptysBio distributed these 100 shares to its own stockholders in a Spin-Off that occurred before the market opened that day. Following this distribution, AnaptysBio reported holding 0 shares of First Tracks common stock, indicating its ownership position in First Tracks was fully distributed.
First Tracks Biotherapeutics director Magda Marquet reported new equity awards and spin-off related holdings. She holds 9,930 shares of common stock received in the pro rata distribution from AnaptysBio under the Separation and Distribution Agreement. On the derivative side, she was granted 4,000 restricted stock units that vest in full on the company’s 2026 annual meeting date and 6,030 RSUs that vest in full on the 2027 annual meeting date, each RSU convertible into one common share for no cash payment. She also holds multiple stock options to buy First Tracks common stock, including 5,500 options at an exercise price of $11.75 per share that are fully vested and 16,510 options at $3.97 per share that vest monthly over 12 months starting February 6, 2026, along with several older option grants at exercise prices between $6.22 and $8.14 per share.
First Tracks Biotherapeutics, Inc. President and CEO Daniel Faga reported equity awards and holdings rather than open-market trades. He directly holds 496,684 shares of common stock and received multiple grants of restricted stock units, each RSU representing a right to one common share.
The filing also shows several employee stock options to acquire common stock at exercise prices ranging from $3.97 to $11.75 per share with expirations between 2031 and 2036. Footnotes explain these options and RSUs were adjusted and granted in connection with AnaptysBio’s spin-off of First Tracks under a Separation and Distribution Agreement.